Chemicals & Small Molecules

NSC697923 is a cell-permeable and selective inhibitor of the Ub-conjugating enzyme (E2) complex Ubc13-Uev1A. It is believed to act by disrupting formation of the Ubc13:Ub conjugate. Shown to inhibit proliferation and survival of certain B-cell lymphoma cells.

NSC697923 is a cell-permeable and selective inhibitor of the Ub-conjugating enzyme (E2) complex Ubc13-Uev1A. It is believed to act by disrupting formation of the Ubc13:Ub conjugate. Shown to inhibit proliferation and survival of certain B-cell lymphoma cells.

NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 (also known as VER-82576) is a novel ATP-competitive HSP90β inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Heat shock protein 90 (Hsp90). NVP-BEP800 induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model. NVP-BEP800 can radiosensitise tumour cell lines of different entities through destabilisation and depletion of several Hsp90 client proteins, thus causing the depletion of S phase and G2/M arrest, increased DNA damage and repair protraction and, to some extent, apoptosis.

NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 (also known as VER-82576) is a novel ATP-competitive HSP90β inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Heat shock protein 90 (Hsp90). NVP-BEP800 induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model. NVP-BEP800 can radiosensitise tumour cell lines of different entities through destabilisation and depletion of several Hsp90 client proteins, thus causing the depletion of S phase and G2/M arrest, increased DNA damage and repair protraction and, to some extent, apoptosis.

NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 (also known as VER-82576) is a novel ATP-competitive HSP90β inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Heat shock protein 90 (Hsp90). NVP-BEP800 induced robust antitumor responses in tumor xenograft models, including regression in the BT-474 breast cancer model. NVP-BEP800 can radiosensitise tumour cell lines of different entities through destabilisation and depletion of several Hsp90 client proteins, thus causing the depletion of S phase and G2/M arrest, increased DNA damage and repair protraction and, to some extent, apoptosis.

P005091 is a selective, potent inhibitor of USP7 deubiquitylating activity.

P005091 is a selective, potent inhibitor of USP7 deubiquitylating activity.

Parthenolide specifically inhibits HDAC1 without affecting other class I/II HDACs.

Parthenolide specifically inhibits HDAC1 without affecting other class I/II HDACs.